157 related articles for article (PubMed ID: 27445164)
1. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
Badve SV; Pascoe EM; Burke M; Clayton PA; Campbell SB; Hawley CM; Lim WH; McDonald SP; Wong G; Johnson DW
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1845-1855. PubMed ID: 27445164
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin.
Cortazar F; Molnar MZ; Isakova T; Czira ME; Kovesdy CP; Roth D; Mucsi I; Wolf M
Am J Transplant; 2012 Feb; 12(2):379-87. PubMed ID: 22054244
[TBL] [Abstract][Full Text] [Related]
3. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
4. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
[TBL] [Abstract][Full Text] [Related]
5. Pretransplant Cancer in Kidney Recipients in Relation to Recurrent and De Novo Cancer Incidence Posttransplantation and Implications for Graft and Patient Survival.
Unterrainer C; Opelz G; Döhler B; Süsal C;
Transplantation; 2019 Mar; 103(3):581-587. PubMed ID: 30418430
[TBL] [Abstract][Full Text] [Related]
6. Association of prevalent vascular disease with allograft failure and mortality in live-donor kidney transplant recipients - a retrospective cohort study.
Mainra R; Wong G; Pilmore H; Lim WH
Transpl Int; 2019 Nov; 32(11):1161-1172. PubMed ID: 31241216
[TBL] [Abstract][Full Text] [Related]
7. Post-Transplant Hypophosphatemia and the Risk of Death-Censored Graft Failure and Mortality after Kidney Transplantation.
van Londen M; Aarts BM; Deetman PE; van der Weijden J; Eisenga MF; Navis G; Bakker SJL; de Borst MH;
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1301-1310. PubMed ID: 28546442
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
9. Use of Mammalian Target of Rapamycin Inhibitors for Pancreas Transplant Immunosuppression Is Associated With Improved Allograft Survival and Improved Early Patient Survival.
Siskind EJ; Liu C; Collins DT; Emery E; Steen E; Tran E; Stodghill J; Piper J; Jonsson J; Ortiz J
Pancreas; 2019; 48(5):644-651. PubMed ID: 31091210
[TBL] [Abstract][Full Text] [Related]
10. Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials.
Ying T; Wong G; Lim WH; Clayton P; Kanellis J; Pilmore H; Campbell S; O'Connell PJ; Russ G; Chadban S
Transplantation; 2019 Aug; 103(8):1705-1713. PubMed ID: 30365464
[TBL] [Abstract][Full Text] [Related]
11. Nonmelanoma Skin Cancers After Kidney Transplant: Our 15 Years of Experience With Mammalian Target of Rapamycin Inhibitors.
Okut G; Alp A; Tatar E; Simsek C; Tugmen C; Uslu A
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):236-239. PubMed ID: 28260475
[TBL] [Abstract][Full Text] [Related]
12. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
13. Mortality and Allograft Loss Trends Among US Pediatric Kidney Transplant Recipients With and Without Focal Segmental Glomerulosclerosis.
Wang CS; Gander J; Patzer RE; Greenbaum LA
Am J Kidney Dis; 2018 Mar; 71(3):392-398. PubMed ID: 29277509
[TBL] [Abstract][Full Text] [Related]
14. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Kidney Transplantation Abroad: A Single-Center Canadian Cohort Study.
Quach K; Sultan H; Li Y; Famure O; Kim SJ
Prog Transplant; 2016 Mar; 26(1):5-12. PubMed ID: 27136244
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
18. Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients.
Dahle DO; Grotmol T; Leivestad T; Hartmann A; Midtvedt K; Reisæter AV; Mjøen G; Pihlstrøm HK; Næss H; Holdaas H
Transplantation; 2017 Oct; 101(10):2599-2605. PubMed ID: 28207636
[TBL] [Abstract][Full Text] [Related]
19. De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study.
Ying T; Wong G; Lim W; Kanellis J; Pilmore H; Campbell S; Masterson R; Walker R; O'Connell P; Russ G; Chadban S
Am J Transplant; 2018 Dec; 18(12):2977-2986. PubMed ID: 29802791
[TBL] [Abstract][Full Text] [Related]
20. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
